NCT02968004Phase 3Completed

Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2019-08Actual

Enrollment · participants224Actual

Source updated2025-07-20Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Pediatric Growth Hormone Deficiency

Treatments or interventions studied

MOD-4023DrugAlso known as Somatrogon
SomatropinDrugAlso known as Genotropin

Primary outcomes · main study measures

measure: Annual Height Velocity in Main Study Phase; description: Annual Height Velocity in cm. Annual Height Velocity at 12 months is based on the difference between the heights at 12 months and baseline.; timeFrame: 52 weeks; measure: Annual Height Velocity in OLE Phase; description: Annualized Height Velocity (cm/year) in OLE Phase; timeFrame: Up to 60 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history